Neuromodulation for Hypothalamic Obesity

Sponsor
University of British Columbia (Other)
Overall Status
Withdrawn
CT.gov ID
NCT03708913
Collaborator
(none)
0
1
1
10
0

Study Details

Study Description

Brief Summary

The balance between hunger and satiety is imperative for an individual's survival and overall health.). Without this balance, individuals can become morbidly obese or lack adequate nutrition for survival. Craniopharyngioma (CP) is a benign tumour that occurs at the base of the brain in children. Unfortunately, pediatric neurosurgeons sometimes inadvertently destroy a child's satiety centre during CP tumour removal surgery. This leaves the child with a post-operative complication: an insatiable appetite. This form of obesity is called "hypothalamic obesity". This study is designed to investigate Deep Brain Stimulation for hypothalamic obesity in n=6 young adults who have stabilized tumours.

Condition or Disease Intervention/Treatment Phase
  • Device: Hypothalamic Deep Brain Stimulation
N/A

Detailed Description

For young adults with destroyed satiety centres due to childhood CP surgery, we believe directly re-balancing the brain's control of hunger and satiety is necessary for sustained and long-term therapy. n=6 patients will be recruited in this Phase 1 DBS trial. The proposed research will hope to improve personal health among the young adults involved in this study by improving quality of life and avoiding long-term cardiovascular morbidities. Furthermore, this study will elucidate what brain regions drive excessive hunger and develop a treatment that attempts to reverse these abnormalities.

Study Design

Study Type:
Interventional
Actual Enrollment :
0 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Deep Brain Stimulation for Hypothalamic Obesity: A Surgical & Neuroimaging Study
Actual Study Start Date :
Jun 1, 2019
Actual Primary Completion Date :
Dec 1, 2019
Actual Study Completion Date :
Apr 1, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: Open-Label Lateral Hypothalamic DBS Stimulation

Open-label lateral hypothalamic DBS stimulation for 1 year.

Device: Hypothalamic Deep Brain Stimulation
One-year continuous hypothalamic deep brain stimulation

Outcome Measures

Primary Outcome Measures

  1. Number of Participants With Adverse Events That Are Related to surgery and Post-Operative Side Effects [12 months]

Secondary Outcome Measures

  1. Body Mass Index (BMI) [12 months]

    Measuring BMI(kg/m^2) following 12 months of constant stimulation

  2. Hyperphagia Questionnaire [12 months]

    Completion of hyperphagia questionnaire

  3. SF-36 Quality of Life Questionnaire [12 months]

    Completion of QoL Questionnaire

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 30 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Diagnosed with hypothalamic obesity following craniopharyngioma tumour removal

  • Treatment refractory to pharmacological interventions such as growth hormone therapy and anti-obesity medications

Exclusion Criteria:
  • Unable to give consent or unmanaged psychiatric condition

Contacts and Locations

Locations

Site City State Country Postal Code
1 Leslie and Gordon Diamond Health Center Vancouver British Columbia Canada V5Z1M9

Sponsors and Collaborators

  • University of British Columbia

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Christopher Honey, Professor & Neurosurgeon, University of British Columbia
ClinicalTrials.gov Identifier:
NCT03708913
Other Study ID Numbers:
  • H16-01595
First Posted:
Oct 17, 2018
Last Update Posted:
Nov 2, 2020
Last Verified:
Oct 1, 2020
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 2, 2020